Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Drug-Linker Conjugates for ADC
    (19)
  • Antibody-Drug Conjugates (ADCs)
    (7)
  • ADC Linker
    (4)
  • EGFR
    (3)
  • ADC Antibody
    (2)
  • ADC Cytotoxin
    (1)
  • Microtubule Associated
    (1)
  • PSMA
    (1)
  • STING
    (1)
  • c-Met/HGFR
    (1)
Filter
Search Result
Results for "

linker-payload

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    39
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    10
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    13
    TargetMol | PROTAC
Lys-SMCC-DM1
Lys-Nε-MCC-DM1
T119171281816-04-3
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
m-PEG4-Br
T15872110429-45-3
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) for Trastuzumab, positioned distally from the monomethyl auristatin E (MMAE) payload to produce an ADC with modified hydrophilicity, antigen binding, and in vitro potency[1].
  • Inquiry Price
7-10 days
Size
QTY
DBCO-(PEG2-VC-PAB-MMAE)2
T177892259318-55-1
DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a potent tubulin inhibitor and toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2, serving as the cytotoxic component in this formulation.
  • Inquiry Price
Size
QTY
DBCO-PEG4-SS-TCO
T17799
DBCO-PEG4-SS-TCO is a cleavable 4-unit polyethylene glycol (PEG) linker crucial for the synthesis of antibody-drug conjugates (ADCs)[1], facilitating the connection of the drug payload to the antibody and enabling targeted drug delivery.
  • Inquiry Price
Size
QTY
DBCO-(PEG)3-VC-PAB-MMAE
T17817
DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, is conjugated via a DBCO-(PEG)3-vc-PAB linker.
  • Inquiry Price
Size
QTY
Mal-Phe-C4-VC-PAB-MMAE
T183032259318-51-7
Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.
  • Inquiry Price
Size
QTY
NAMPT inhibitor-linker 1
T184772241019-57-6
NAMPT inhibitor-linker 1, a drug-linker conjugate for ADC, integrates an NAMPT inhibitor (as a payload) with a linker. In the formulation of ADC-3, it pairs with an anti-c-Kit monoclonal antibody, demonstrating strong efficacy against c-Kit expressing cell lines, specifically GIST-T1 and NCI-H526, where it exhibits IC50 values of <3 pM and 9 pM, respectively.
  • Inquiry Price
Size
QTY
NAMPT inhibitor-linker 2
T184782241014-82-2
NAMPT inhibitor-linker 2, a drug-linker conjugate for antibody-drug conjugates (ADCs), comprises an NAMPT inhibitor payload and a linker. When combined with an anti-c-Kit monoclonal antibody to form ADC-4, it demonstrates potent efficacy against c-Kit expressing cell lines, including GIST-T1 and NCI-H526, with IC50 values of <7 pM and 40 pM, respectively.
  • Inquiry Price
Size
QTY
PC Mal-NHS carbonate ester
T185221408057-91-9
PC Mal-NHS carbonate ester is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1]. This chemical compound facilitates drug-antibody conjugation, enabling targeted delivery and enhanced therapeutic efficacy. Its unique carbonate ester structure allows efficient cleavage in the targeted environment, ensuring controlled drug payload release, highlighting its significance in innovative and targeted cancer therapies.
  • Inquiry Price
Size
QTY
SPDB-DM4
T187011626359-62-3
SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.
  • Inquiry Price
Size
QTY
sulfo-SPDB-DM4
T187301626359-59-8
Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.
  • Inquiry Price
Size
QTY
MC-Val-Cit-PAB-Sunitinib
T204287
MC-Val-Cit-PAB-Sunitinib is a conjugate composed of the payload Sunitinib and a linker. It is utilized in the synthesis of HR97-Sunitinib.
  • Inquiry Price
Size
QTY
Thailanstatin A
T388891426953-21-0
Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50 = 650 nM). It inhibits multiple cancer cell lines via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome, displaying low-nM to sub-nM IC50s. Thailanstatin A, as a payload for ADCs, is conjugated to the lysines on trastuzumab, yielding linker-less ADC.
  • Inquiry Price
Size
QTY